Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Exalenz Dual Mode System Compared to Biopsy for H.Pylori Detection
Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the Dual Mode BreathID® Hp System Compared to Biopsy Results
Status: Enrolling
Updated:  7/5/2016
Gasrtrenetrology Associates of Western Michigan, West Michigan Clinical Research Center
mi
from
Wyoming, MI
Exalenz Dual Mode System Compared to Biopsy for H.Pylori Detection
Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the Dual Mode BreathID® Hp System Compared to Biopsy Results
Status: Enrolling
Updated: 7/5/2016
Gasrtrenetrology Associates of Western Michigan, West Michigan Clinical Research Center
mi
from
Wyoming, MI
Click here to add this to my saved trials
Exalenz Dual Mode System Compared to Biopsy for H.Pylori Detection
Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the Dual Mode BreathID® Hp System Compared to Biopsy Results
Status: Enrolling
Updated:  7/5/2016
Digestive Disease Care, PC
mi
from
New Hyde Park, NY
Exalenz Dual Mode System Compared to Biopsy for H.Pylori Detection
Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the Dual Mode BreathID® Hp System Compared to Biopsy Results
Status: Enrolling
Updated: 7/5/2016
Digestive Disease Care, PC
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Exalenz Dual Mode System Compared to Biopsy for H.Pylori Detection
Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the Dual Mode BreathID® Hp System Compared to Biopsy Results
Status: Enrolling
Updated:  7/5/2016
Great Lakes Medical Research, LLC
mi
from
Willoughby, OH
Exalenz Dual Mode System Compared to Biopsy for H.Pylori Detection
Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the Dual Mode BreathID® Hp System Compared to Biopsy Results
Status: Enrolling
Updated: 7/5/2016
Great Lakes Medical Research, LLC
mi
from
Willoughby, OH
Click here to add this to my saved trials
Exalenz Dual Mode System Compared to Biopsy for H.Pylori Detection
Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the Dual Mode BreathID® Hp System Compared to Biopsy Results
Status: Enrolling
Updated:  7/5/2016
Innovative Clinical Research
mi
from
Rapd City, SD
Exalenz Dual Mode System Compared to Biopsy for H.Pylori Detection
Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the Dual Mode BreathID® Hp System Compared to Biopsy Results
Status: Enrolling
Updated: 7/5/2016
Innovative Clinical Research
mi
from
Rapd City, SD
Click here to add this to my saved trials
Exalenz Dual Mode System Compared to Biopsy for H.Pylori Detection
Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the Dual Mode BreathID® Hp System Compared to Biopsy Results
Status: Enrolling
Updated:  7/5/2016
Digestive Disease Center of South Texas, P.L.L.C
mi
from
San Antonio, TX
Exalenz Dual Mode System Compared to Biopsy for H.Pylori Detection
Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the Dual Mode BreathID® Hp System Compared to Biopsy Results
Status: Enrolling
Updated: 7/5/2016
Digestive Disease Center of South Texas, P.L.L.C
mi
from
San Antonio, TX
Click here to add this to my saved trials
Exalenz Dual Mode System Compared to Biopsy for H.Pylori Detection
Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the Dual Mode BreathID® Hp System Compared to Biopsy Results
Status: Enrolling
Updated:  7/5/2016
Barzilai Medical Center
mi
from
Ashkelon,
Exalenz Dual Mode System Compared to Biopsy for H.Pylori Detection
Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the Dual Mode BreathID® Hp System Compared to Biopsy Results
Status: Enrolling
Updated: 7/5/2016
Barzilai Medical Center
mi
from
Ashkelon,
Click here to add this to my saved trials
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
Hematopoietic Stem Cell Transplantation Using Alternate Donor Umbilical Cord Blood Options
Status: Enrolling
Updated:  7/13/2016
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
Hematopoietic Stem Cell Transplantation Using Alternate Donor Umbilical Cord Blood Options
Status: Enrolling
Updated: 7/13/2016
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
The Johns Hopkins Transplant Infectious Diseases Prospective Cohort Study
The Johns Hopkins Transplant Infectious Diseases Prospective Cohort Study
Status: Enrolling
Updated:  7/18/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
The Johns Hopkins Transplant Infectious Diseases Prospective Cohort Study
The Johns Hopkins Transplant Infectious Diseases Prospective Cohort Study
Status: Enrolling
Updated: 7/18/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
North Little Rock, AR
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
North Little Rock, AR
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Sacremento, CA
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Sacremento, CA
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Bay Pines, FL
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Bay Pines, FL
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Coral Springs, FL
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Coral Springs, FL
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Miami, FL
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Idaho Falls, ID
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Chicago, IL
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Lafayette, IN
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Lafayette, IN
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Lexington, KY
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Rochester, MN
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
St. Paul, MN
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
St. Paul, MN
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
St. Louis, MO
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Omaha, NE
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Flushing, NY
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Flushing, NY
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Rochester, NY
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Syracuse, NY
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Syracuse, NY
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Fargo, ND
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Fargo, ND
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Lima, OH
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Lima, OH
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Jackson, TN
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Jackson, TN
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Houston, TX
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Springfield, VA
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Springfield, VA
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Virginia Beach, VA
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Gainesville, FL
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Maywood, IL
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Maywood, IL
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Detroit, MI
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Bronx, NY
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  7/25/2016
mi
from
Vancouver,
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 7/25/2016
mi
from
Vancouver,
Click here to add this to my saved trials
Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults
Phase 1 Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H7N9 (6-2) AA ca Recombinant (A/Anhui/1/2013 (H7N9) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H7N9 Disease in the Event of a Pandemic
Status: Enrolling
Updated:  7/26/2016
Univ of Rochester Medical Center
mi
from
Rochester, NY
Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults
Phase 1 Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H7N9 (6-2) AA ca Recombinant (A/Anhui/1/2013 (H7N9) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H7N9 Disease in the Event of a Pandemic
Status: Enrolling
Updated: 7/26/2016
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated:  7/26/2016
Clinical Research Facility
mi
from
Birmingham, AL
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated: 7/26/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated:  7/26/2016
Clinical Research Facility
mi
from
Dothan, AL
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated: 7/26/2016
Clinical Research Facility
mi
from
Dothan, AL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated:  7/26/2016
Clinical Research Facility
mi
from
Phoenix, AZ
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated: 7/26/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated:  7/26/2016
Clinical Research Facility
mi
from
Bakersfield, CA
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated: 7/26/2016
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated:  7/26/2016
Clinical Research Facility
mi
from
Coronado, CA
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated: 7/26/2016
Clinical Research Facility
mi
from
Coronado, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated:  7/26/2016
Clinical Research Facility
mi
from
La Jolla, CA
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated: 7/26/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated:  7/26/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated: 7/26/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated:  7/26/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated: 7/26/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated:  7/26/2016
Clinical Research Facility
mi
from
Sacramento, CA
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated: 7/26/2016
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated:  7/26/2016
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated: 7/26/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated:  7/26/2016
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated: 7/26/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated:  7/26/2016
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
Status: Enrolling
Updated: 7/26/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials